We are live on ! Find out more
BDRX icon

Biodexa Pharmaceuticals
BDRX

4 hedge funds and large institutions have $87.3K invested in Biodexa Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more capital inflows, than outflows

Capital inflows: $172K | Capital outflows: $101K

1.09% more ownership

Funds ownership: 1.04% → 2.13% (+1.1%)

33% less funds holding

Funds holding: 6 → 4 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
4
Holders Change
-2
Holders Change %
-33.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$153K
2
Morgan Stanley
Morgan Stanley
New York
+$6.13K
3
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$6.13K
4
Two Sigma Securities
Two Sigma Securities
New York
+$6.13K

Top Sellers

Rank Fund Capital Flow
1
Virtu Financial
Virtu Financial
New York
-$32K
2
Citadel Advisors
Citadel Advisors
Florida
-$30K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$27K
4
GSC
Ground Swell Capital
South Carolina
-$11.7K
5
Bank of America
Bank of America
North Carolina
-$769

BDRX Hedge Fund Activity: Q3 2024 in Review

4 of the 6,987 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q3 2024, worth a combined $87.3K — down 36% from $136K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of BDRX and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was UBS Group, adding an estimated $153K. The largest seller was Virtu Financial, exiting entirely with an estimated $32K sold.

  • 4 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q3 2024, down from 6 in Q2 2024.
  • Funds reported $87.3K of Biodexa Pharmaceuticals stock for Q3 2024, down 36% quarter-over-quarter.
  • 2 funds opened new Biodexa Pharmaceuticals positions in Q3 2024 and 4 closed out, a net change of -2 holders.
  • The largest Biodexa Pharmaceuticals buyer in Q3 2024 was UBS Group, an estimated $153K added.
  • The largest Biodexa Pharmaceuticals seller in Q3 2024 was Virtu Financial, an estimated $32K sold.

Based on aggregated 13F filings for Q3 2024.